MHRA has produced draft GxP data integrity guidance for industry and we welcome your comments
This consultation document
(PDF, 207KB, 14 pages)
provides guidance on the data integrity expectations that should be considered by organisations involved in any aspect of the pharmaceutical lifecycle or GLP studies regulated by MHRA.
The guidance is intended to be a useful resource on the core elements of a compliant data governance system across all GxP sectors (good laboratory practice, good clinical practice, good manufacturing practice, good distribution practice and good pharmacovigilance practice).
It addresses fundamental failures identified by MHRA and international regulatory partners during GLP, GCP, GMP and GDP inspections; many of which have resulted in regulatory action.
The document should be read in conjunction with the applicable regulations and the general guidance specific to each GxP.